A medical affairs buildout for a longstanding global partner.
How we reinforced AstraZeneca's medical affairs team by positioning top-tier professionals, addressing critical needs in niche fields, and expanding our long-term collaboration.
We've been in a longstanding partnership with global pharmaceutical leader, AstraZeneca, when they turned to us to strengthen their medical affairs team. Facing challenges in filling key roles in pancreatic cancer, small cell lung cancer, and hematology, AstraZeneca sought our expertise to identify top-tier medical directors who could drive innovation in these critical fields.
Problems identified
AstraZeneca faced significant challenges in reinforcing their medical affairs team, specifically in the specialized areas of pancreatic cancer, small cell lung cancer, and hematology. They required medical directors with a strong physician background, experienced in these niche fields. The scarcity of local talent in Maryland further complicated their search, necessitating candidates willing to relocate from other parts of the US.
What was at stake
Without securing the right talent, AstraZeneca risked weakening their medical affairs capabilities in critical therapeutic areas. This gap could hinder their ability to advance clinical development and maintain their leadership in oncology and hematology, potentially affecting patient outcomes and their competitive standing in these crucial sectors.
Strategy and approach
Results
Within 13 days, we submitted 15 qualified candidates, with 10 progressing through further rounds. This diligent process resulted in the successful placement of two highly qualified medical directors. Additionally, AstraZeneca opened four new positions across various indications and seniorities based on the quality of the candidates presented.
Impact
These strategic hires have strengthened AstraZeneca's medical affairs capabilities in pancreatic cancer, small cell lung cancer, and hematology. This enhancement supports their clinical development and maintains their leadership in these critical therapeutic areas, ultimately improving patient outcomes and their competitive edge.
Build your own success story.
For support building out your Medical Affairs team like we did with AstraZeneca, get in touch today. Provide detail about your current talent needs below, and let's build a winning strategy together.
Explore similar projects.
We began working with Ablative after a major funding round, where they had their initial sights set on the launch of their clinical program within Europe and required staff across 8 sites.
Uncover how we filled two critical VP of Clinical Development roles for AskBio, enabling the timely launch of their Global Phase II study within tight deadlines.
With fast-tracked designation for their lead product, AveXis required highly-skilled candidates with expertise in neuroscience and orphan diseases to lead their product to commercialization.